Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Astellas Dissolves Drug Development Pacts
by Lisa M. Jarvis
March 18, 2013
| A version of this story appeared in
Volume 91, Issue 11
Astellas Pharma has given back to Cubist Pharmaceuticals the rights to the antibiotic ceftolozane, which is currently being tested in combination with tazobactam in two Phase III studies to treat infections caused by gram-negative bacteria. Astellas, which owned the rights to develop the drug in Asia-Pacific and the Middle East, gets a $25 million up-front fee from Cubist. Astellas has also ended a cancer drug development partnership with Ambit Biosciences. The biotech firm now owns full rights to quizartinib, an FLT3 inhibitor in a Phase IIb study for the treatment of refractory acute myeloid leukemia.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X